title: [Influence of SNCG transfection on the effectiveness of anti-tumor drugs in PC-3 cell lines].
abstract: OBJECTIVE
  To observe the sensitivity of the PC-3 cell lines transfected with the PCI-NEO-SNCG plasmid to Cisplatin (DDP), 5-Fluorouracil (5-FU), Adriamycin (ADM), Vincristine (VCR) and Paclitaxel (TAX), and to explore the influence of the SNCG expression on the effectiveness of anti-tumor drugs.
  
  
  METHODS
  The plasmids PCI-NEO and PCI-NEO-SNCG were transfected into the hormone-independent prostate cancer cell lines PC-3. RT-PCR was adopted to examine the expression of SNCG in the PC-3 cell lines. The MTT method was employed to detect the suppressive effects of different anti-tumor drugs (DDP, ADM, 5-FU, VCR and TAX) on the cell lines transfected with PCI-NEO and PCI-NEO-SNCG. Flow cytometry was used to analyze the cell cycles and apoptosis of the transfected cells treated with TAX.
  
  
  RESULTS
  The 5 anti-tumor drugs suppressed the growth of the cell lines transfected with the plasmids PCI-NEO and PCI-NEO-SNCG in a time-dependant manner. The comparison between the growth-suppressing effects of different anti-tumor drugs on the PC-3 cell lines showed no significant differences between the group transfected with PCI-NEO and that with PCI-NEO-SNCG in DDP, 5-FU, ADM and VCR (P > 0.05), while the rate of suppression of TAX on the latter cell lines was significantly lower than that on the former (P < 0.01). Compared with the PCI-NEO-SNCG plasmid transfected cell lines, after treated with TAX for 48 hours, those transfected with the PCI-NEO plasmid exhibited a significantly larger proportion of cells remaining in the G2-M stage (P < 0.01), a smaller proportion in the G0-G1 and S stages (P < 0.01) and a significantly higher expression of Caspase-3 (P < 0.01).
  
  
  CONCLUSIONS
  The significant reduction of the growth-suppressing effect of TAX in the SNCG-transfected PC-3 cell lines suggests that the expression of SNCG may restrain the effect of TAX. These findings have provided evidence and guide to the individual chemotherapy of prostate cancer.
authors.affiliation: Department of Life Science, Nanjing Normal University, Nanjing, Jiangsu 210046, China.
authors.forename: Jia-Liang
authors.initials: JL
authors.lastname: Chen
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Li-Rong
authors.initials: LR
authors.lastname: Zhang
authors.forename: Bang-Shun
authors.initials: BS
authors.lastname: He
authors.forename: Yu-Qin
authors.initials: YQ
authors.lastname: Pan
authors.forename: Qing-Di
authors.initials: QD
authors.lastname: Zeng
authors.forename: Hua-Xin
authors.initials: HX
authors.lastname: Jiang
authors.forename: Shu-Kui
authors.initials: SK
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000235:genetics; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D017239:Paclitaxel / Q000494:pharmacology*; D011471:Prostatic Neoplasms; D014162:Transfection; D051845:gamma-Synuclein / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; C104249:SNCG protein, human; D051845:gamma-Synuclein; D017239:Paclitaxel; D002945:Cisplatin